Literature DB >> 16904605

Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected.

Oliver Stoeltzing1, Funda Meric-Bernstam, Lee M Ellis.   

Abstract

In this issue of Cancer Cell, Phung and coworkers demonstrate that sustained endothelial activation of Akt by expression of constitutively activated Akt1 (myrAkt1) leads to blood vessels that essentially recapitulate the complex structural and functional abnormalities of tumor vessels. The authors provide evidence that rapamycin inhibition of PI3K/Akt/mTOR signaling in endothelial cells (ECs), by either reducing Akt activity or blocking mTOR, reverses the pathologic effects associated with excess VEGF signaling in the tumor vasculature. However, unexpected findings following mTOR inhibition in vivo highlight the seemingly paradoxical and complex effects of rapamycin on various cell types within the tumor microenvironment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16904605     DOI: 10.1016/j.ccr.2006.07.013

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  18 in total

Review 1.  Recent progress in histochemistry and cell biology.

Authors:  Stefan Hübner; Athina Efthymiadis
Journal:  Histochem Cell Biol       Date:  2012-02-25       Impact factor: 4.304

2.  Mitotic lymphoma cells are characterized by high expression of phosphorylated ribosomal S6 protein.

Authors:  Gábor Egervári; Agnes Márk; Melinda Hajdu; Gábor Barna; Zoltán Sápi; Tibor Krenács; László Kopper; Anna Sebestyén
Journal:  Histochem Cell Biol       Date:  2011-03-20       Impact factor: 4.304

3.  Phenotype of tumor lymphatic vessels is a prognostic factor in human tongue squamous cell carcinoma.

Authors:  Yukie Nitta; Kyoko Hida; Tetsuya Kitamura; Fumihiro Higashino; Noritaka Ohga; Kazuaki Fukushima; Masanobu Shindoh
Journal:  Oncol Lett       Date:  2010-11-08       Impact factor: 2.967

Review 4.  Inhibitors of mTOR.

Authors:  Heinz-Josef Klümpen; Jos H Beijnen; Howard Gurney; Jan H M Schellens
Journal:  Oncologist       Date:  2010-12-08

5.  Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression.

Authors:  Asish K Ghosh; Charla R Secreto; Traci R Knox; Wei Ding; Debabrata Mukhopadhyay; Neil E Kay
Journal:  Blood       Date:  2009-12-17       Impact factor: 22.113

Review 6.  Protein kinases and associated pathways in pluripotent state and lineage differentiation.

Authors:  Melina Shoni; Kathy O Lui; Demetrios G Vavvas; Michael G Muto; Ross S Berkowitz; Nikolaos Vlahos; Shu-Wing Ng
Journal:  Curr Stem Cell Res Ther       Date:  2014       Impact factor: 3.828

Review 7.  The mTOR signaling pathway as a treatment target for intracranial neoplasms.

Authors:  Doreen Pachow; Wolfgang Wick; David H Gutmann; Christian Mawrin
Journal:  Neuro Oncol       Date:  2014-08-27       Impact factor: 12.300

8.  Rapamycin regulates the phosphorylation of rictor.

Authors:  Argun Akcakanat; Gopal Singh; Mien-Chie Hung; Funda Meric-Bernstam
Journal:  Biochem Biophys Res Commun       Date:  2007-08-08       Impact factor: 3.575

9.  Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability.

Authors:  Qi Xue; Benjamin Hopkins; Carole Perruzzi; Durga Udayakumar; David Sherris; Laura E Benjamin
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

Review 10.  Targeting the mTOR signaling network for cancer therapy.

Authors:  Funda Meric-Bernstam; Ana Maria Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2009-03-30       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.